So AI - Search Results

1

Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.

Sowery RD, Hadaschik BA, So AI, Zoubeidi A, Fazli L, Hurtado-Coll A, Gleave ME. Sowery RD, et al. Among authors: so ai. BJU Int. 2008 Aug;102(3):389-97. doi: 10.1111/j.1464-410X.2008.07618.x. Epub 2008 Mar 11. BJU Int. 2008. PMID: 18336596 Clinical Trial.

2

Androgens and prostate cancer.

So AI, Hurtado-Coll A, Gleave ME. So AI, et al. World J Urol. 2003 Nov;21(5):325-37. doi: 10.1007/s00345-003-0373-9. Epub 2003 Oct 29. World J Urol. 2003. PMID: 14586548 Review.

3

Prostate specific antigen: an updated review.

So A, Goldenberg L, Gleave ME. So A, et al. Can J Urol. 2003 Dec;10(6):2040-50. Can J Urol. 2003. PMID: 14704108 Review.

4

Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress.

Trougakos IP, So A, Jansen B, Gleave ME, Gonos ES. Trougakos IP, et al. Cancer Res. 2004 Mar 1;64(5):1834-42. doi: 10.1158/0008-5472.can-03-2664. Cancer Res. 2004. PMID: 14996747

5

Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo.

July LV, Beraldi E, So A, Fazli L, Evans K, English JC, Gleave ME. July LV, et al. Mol Cancer Ther. 2004 Mar;3(3):223-32. Mol Cancer Ther. 2004. PMID: 15026542

6

Effect of time of castration and tumour volume on time to androgen-independent recurrence in Shionogi tumours.

So AI, Bowden M, Gleave M. So AI, et al. BJU Int. 2004 Apr;93(6):845-50. doi: 10.1111/j.1464-410X.2003.04726.x. BJU Int. 2004. PMID: 15050003

7

Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer kotcc-1 cells.

Miyake H, Eto H, Hara I, So A, Li D, Gleave ME. Miyake H, et al. J Urol. 2004 Jun;171(6 Pt 1):2477-81. doi: 10.1097/01.ju.0000118382.89456.f7. J Urol. 2004. PMID: 15126879

8

Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer.

Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K, Gleave M. Rocchi P, et al. Cancer Res. 2004 Sep 15;64(18):6595-602. doi: 10.1158/0008-5472.CAN-03-3998. Cancer Res. 2004. PMID: 15374973

9

Mechanisms of the development of androgen independence in prostate cancer.

So A, Gleave M, Hurtado-Col A, Nelson C. So A, et al. World J Urol. 2005 Feb;23(1):1-9. doi: 10.1007/s00345-004-0473-1. Epub 2005 Jan 27. World J Urol. 2005. PMID: 15770516 Review.

10

Antisense oligonucleotide therapy in the management of bladder cancer.

So A, Rocchi P, Gleave M. So A, et al. Curr Opin Urol. 2005 Sep;15(5):320-7. doi: 10.1097/01.mou.0000175572.46986.2c. Curr Opin Urol. 2005. PMID: 16093856 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

218 results

Search Page

Filters